Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Policlinico Agostino Gemelli IRCCSRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06867445
- Record updated
- 17 July 2025
- Original description
The aim of this clinical trial is to assess the oncologic safety of minimally invasive pelvic exenteration in patients with recurrence or persistence of cervical or vaginal cancer with pelvic location, suitable for pelvic exenteration according to the ESGO guidelines (European Society of Gynecological Oncology). The primary aim is to assess the 3-year disease-free survival (DFS). The secondary aim is to assess the 3-year overall survival (OS), the intraoperative and post-operative complication rate, and the patient's quality of life.Read full original descriptionShow less
The aim of this clinical trial is to assess the oncologic safety of minimally invasive pelvic exenteration in patients with recurrence or persistence of cervical or vaginal cancer with pelvic location, suitable for pelvic exenteration according to the ESGO guidelines (European Society of Gynecological Oncology). The primary aim is to assess the 3-year disease-free survival (DFS). The secondary aim is to assess the 3-year overall survival (OS), the intraoperative and post-operative complication rate, and the patient's quality of life.
Inclusion: Diagnosis of recurrent or persistent vaginal or cervical cancer; Proven histological diagnosis of squamous carcinoma, adenocarcinoma or adenosquamous carcinoma; Isolated central pelvic recurrence; MRI-measured maximum tumor diameter ≤ 50 mm; Age > 18 years; Patients who have signed an approved informed consent form; Patients must be suitable for surgery; ECOG Performance Status of 0, 1 or 2 (Eastern Cooperative Oncology Group).
Exclusion: Contraindications to surgery; Serious concomitant systemic disorders incompatible with surgery or minimally invasive surgery (at the discretion of the investigator); Para-aortic lymph nodes with a short-axis diameter ≥ 15 mm on MRI scan and/or SUV max ≥ 2.5 on PET/CT scan; Involvement of lateral pelvic structures (on preoperative imaging or during examination under anaesthesia); Sciatic nerve involvement (at pre-operative imaging or during examination under anaesthesia); Distant metastasis at PET/CT scan; Any histological type other than squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma; Women unable to tolerate prolonged lithotomy and steep Trendelenburg positions; Women with secondary invasive neoplasm in the last 5 years.